Posts

Attention: Fraudulent activity from unsupported accommodation providers

10 April, 2025

We have noticed fraudulent activity from unsupported accommodation providers contacting delegates and speakers to book your accommodation at APLAR 2022, 2023, 2024 and 2025. These companies are not supported by APLAR or the congress organisers. If you have been contacted directly to book accommodation, please do not engage, or proceed with booking your hotel. All accommodation bookings can be made with the APLAR congress secretariat via info@aplarcongress.com or directly through the website: https://aplarcongress.com/accommodation/ Please report any suspicious accommodation communications to info@aplarcongress.com

Morning Symposium 8

8 April, 2025

Shifting the Trajectory: Understanding the Implications of an early subcutaneous application of Methotrexate Early use of subcutaneous methotrexate MTX can shift the treatment trajectory by improving disease control, reducing side effects, and delaying other therapies. It is particularly valuable for patients with oral intolerance or inadequate response to oral MTX. Therefore subcutaneous MTX plays an increasingly important role in the treatment of rheumatoid arthritis (RA) because it offers clinical advantages compared to oral use: Greater Clinical EfficacyStudies show that patients

Lunch symposium 4

8 April, 2025

Norway was one of the first countries to implement widespread biosimilar use, led by pioneering research such as the NOR-SWITCH study. This session features Professor Tore K. Kvien, who will share his extensive, decade-long experience with biosimilars in clinical practice. The discussion will move beyond theoretical benefits to focus on long-term real-world data, the evolution of clinician and patient perspectives, and the practical “Experience” that has shaped current rheumatology standards. This is a unique opportunity to learn from the definitive

Clinical Review Course for RMDs

4 February, 2025

Synopsis: This workshop offers a comprehensive clinical review of major rheumatic diseases, integrating updated therapeutic strategies with essential principles of interventional rheumatology relevant to contemporary clinical practice. Session 1: Major Disease Update Review (I) will focus on rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Key topics include treat-to-target strategies in rheumatoid arthritis, domain-based and pathway-based treatment approaches in psoriatic arthritis, and comprehensive management of systemic lupus erythematosus, addressing both renal and non-renal involvement. The session aims to provide a

GRAPPA Workshop

4 February, 2025

Sponsored by Lilly Synopsis: Obesity is a major comorbidity in psoriatic disease. It increases inflammation, worsens disease severity, reduces treatment response, and raises cardiovascular risks and mortality. This GRAPPA workshop aims to equip rheumatologists and healthcare providers with evidence-based, multidisciplinary education on the link between psoriasis and obesity, along with updates on new therapeutic options. Workshop learning objectives: By the end of the workshop, participants will be able to: Describe the epidemiology, pathology, and impact of obesity on psoriasis (PsO) and psoriatic

Congress Travel Grants

24 January, 2025

APLAR Travel Grant Invitation The Asia-Pacific League of Associations for Rheumatology (APLAR) once again invites all APLAR Young Rheumatologists (AYR) to submit their application for the APLAR Congress Travel Grant. APLAR will grant 50 need-based travel stipends to AYR members with an accepted abstract for a poster or oral presentation for 2025. The grant assists AYR in covering part of the travel expenses for attending the APLAR Congress. The grant will include complimentary registration to the Congress and allowance to

On Demand registration is closed for APLAR 2024

9 September, 2024

Thank you for the interest in on-demand registrations for APLAR 2024. On-demand registration is now closed. We appreciate your enthusiasm and support. Stay tuned for updates on future congresses and opportunities to engage with the APLAR community.

Abstract submissions for APLAR 2025 now open

9 September, 2024

And will close in March 2025. We invite you to submit an abstract to The 27th Asia-Pacific League of Associations for Rheumatology Congress, set to take place in Fukuoka. Now is your opportunity to submit your work, be recognised within the rheumatology community and be part of the official program! Presentation types can include oral or poster presentations. Should you have any questions and enquiries about abstracts, speakers, or program information please reach out to the Program Manager.

APLAR 2024 Wrap

26 August, 2024

Missed out on APLAR 2024? Check out what you missed here!

On Demand registration is now open for APLAR 2024

25 August, 2024

As an APLAR 2024 attendee, you can re-watch all streamed content for 12 months! Watch the sessions you missed, or revisit over 250 expert presentations from the comfort of your home or office through our app. You can still sign up and have 12-month access to the on-demand sessions. See the On-Demand Registration Portal for more information Keep learning from Asia-Pacific’s leading rheumatology experts!

Attention: Fraudulent activity from unsupported accommodation providers

Morning Symposium 8

Lunch symposium 4

Clinical Review Course for RMDs

GRAPPA Workshop

Congress Travel Grants

On Demand registration is closed for APLAR 2024

Abstract submissions for APLAR 2025 now open

APLAR 2024 Wrap

On Demand registration is now open for APLAR 2024

Key dates

About

Abstracts

Program

Destination

Partnership / Exhibition

Follow

Posts

Key dates

The countdown is on